Gordon Dunn
Known title: Chief Financial OfficerCIK: 0001958139
Gordon Dunn's purchase track record
Gordon Dunn has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/23/2024 | QNRX | $55K | -43.3% | -53.0% | +0.9% |
| 9/9/2024 | QNRX | $23K | -18.8% | -69.5% | +2.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| QNRX | ▲ Buy | Open Market | 122,221 | $55K | 12/23/2024 | View on chart |
| QNRX | ▲ Buy | Open Market | 10,000 | $9K | 9/10/2024 | View on chart |
| QNRX | ▲ Buy | Open Market | 10,000 | $7K | 9/10/2024 | View on chart |
| QNRX | ▲ Buy | Open Market | 4,000 | $3K | 9/9/2024 | View on chart |
| QNRX | ▲ Buy | Open Market | 856 | $685 | 9/9/2024 | View on chart |
| QNRX | ▲ Buy | Open Market | 4,000 | $3K | 9/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
QNRX: Manuscript Acceptance for QRX003 in Dermatology
Quoin Pharmaceuticals announced that a manuscript on its drug QRX003 for Netherton syndrome has been accepted for publication in Dermatology and Therapy. The paper includes a pediatric compassionate‑use case report, highlighting early clinical experience. Acceptance may support the company’s ongoing development and regulatory discussions. The news comes as the stock trades near its 14‑day support level.
QNRX: Manuscript Acceptance for QRX003 in Dermatology. Quoin Pharmaceuticals announced that a manuscript on its drug QRX003 for Netherton syndrome has been accepted for publication in Dermatology and Therapy. The paper includes a pediatric compassionate‑use case report, highlighting early clinical experience. Acceptance may support the company’s ongoing development and regulatory discussions. The news comes as the stock trades near its 14‑day support level.